SEC Form 4 · accession 0001140361-15-024640
OncoMed Pharmaceuticals Inc · OMED
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
John A. Lewicki
Officer — EVP & Chief Scientific Officer
Period of report
Jun 15, 2015
Accepted (ET)
Jun 17, 2015 · 5:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001302573
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF2 | Jun 15, 2015 | M | 8,500 | $1.43 | A | 28,500 | D | |
| Common StockF3,F2 | Jun 15, 2015 | S | 8,500 | $24.9167 | D | 20,000 | D | |
| Common StockF2 | Jun 16, 2015 | M | 5,602 | $1.43 | A | 25,602 | D | |
| Common StockF2 | Jun 16, 2015 | M | 2,898 | $3.42 | A | 28,500 | D | |
| Common StockF4,F2 | Jun 16, 2015 | S | 8,500 | $25.2156 | D | 20,000 | D | |
| Common StockF5 | holding | — | — | — | 84,815 | I | See Footnote |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F6 | $1.43 | Jun 15, 2015 | M | 8,500 | D | — | Jan 11, 2017 | Common Stock | 8,500 | 14,777 | D |
| Stock Option (Right to Buy)F6 | $1.43 | Jun 16, 2015 | M | 5,602 | D | — | Jan 11, 2017 | Common Stock | 5,602 | 9,175 | D |
| Stock Option (Right to Buy)F6 | $3.42 | Jun 16, 2015 | M | 2,898 | D | — | Dec 4, 2018 | Common Stock | 2,898 | 134,423 | D |
Explanation of responses
- F1Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on December 16, 2014.
- F2Includes 20,000 restricted stock units. The Reporting Person is entitled to receive one (1) share of common stock for each one (1) restricted stock unit. Also reflects the prior transfer of 1,285 shares of common stock to the reporting person's trust.
- F3This transaction was executed in multiple trades in prices ranging from $24.40 to $25.19, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F4This transaction was executed in multiple trades in prices ranging from $24.87 to $25.44, inclusive. The price reported in Column 4 above reflects the weighted average sales price. The Reporting Person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.
- F5The shares are held by John Allan Lewicki and Jenniffer Joan Lewicki, Trustees of the Lewicki Family Trust dated December 6, 2000.
- F6The option is fully vested and exercisable, subject to an annual limitation of 175,438 shares that can be issued to a single grantee upon the exercise of awards under the Issuer's 2004 Stock Incentive Plan.